Telomerase therapeutics for cancer: challenges and new directions

被引：364

作者：

Shay, Jerry W. ^{[1
]}

Wright, Woodring E. ^{[1
]}

机构：

[1] UT SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 07期

关键词：

D O I：

10.1038/nrd2081

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

It has been approximately a decade since telomerase was described as an almost universal marker for human cancer. Most human tumours not only express telomerase but also have very short telomeres, whereas telomerase activity is either reduced or absent in normal tissues, making the inhibition of telomerase an attractive target for cancer therapeutics. Here we review the current status of telomerase therapeutics and discuss future opportunities and challenges for telomerase research, including a possible relationship with cancer stem cells that could be a source of chemo-/radioresistance development in many advanced cancers.

引用

页码：577 / 584

页数：8

共 89 条

[1] Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells [J].